retatrutide trials weight loss (“reta”) is an experimental weight-loss drug currently in Phase 3 clinical trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works Experimental drug Retatrutide shows promising

If a product description includes spelling errors or terms such as compounded, generic version or same active ingredient as [brand name], it often indicates that the product is a compounded formulation

doi: 10.3389/fendo.2021.721135 Received 06 June 2021 Accepted 05 August 2021 Published 23 August 2021 Volume 12 - 2021 Edited by Kazunori Sango, Tokyo Metropolitan Institute of Medical Science, Japan Reviewed by Mohammad Qaddoumi, Kuwait University, Kuwait

But the glucagon receptor is where retatrutide truly separates itself

Semaglutide GLP-1 has been shown to reduce visceral adipose tissue, or belly fat, in patients with obesity

This is not unusual and reflects the complex interplay of slowed gastric emptying (which promotes constipation) and altered intestinal motility (which can trigger diarrhea)